Abstract
1,25-Dihydroxyvitamin D3 (DHVD3) coadministered with monovalent inactivated poliovirus vaccine (IPV) of all 3 serotypes significantly enhances antipoliovirus systemic and mucosal immunity in mice. Although serum immunoglobulin G antibodies are significantly higher in serotypes 2 and 3, and although salivary immunoglobulin A is significantly increased in serotypes 1 and 3, DHVD3 had the most dramatic effect on the level of neutralizing serum antibodies of all 3 IPV serotypes. These findings suggest a possible use of vitamin D3 as an adjuvant for currently used and proposed new Sabin IPVs.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Disease Models, Animal
-
Immunity / drug effects
-
Immunity, Mucosal / drug effects*
-
Mice
-
Poliomyelitis / blood
-
Poliomyelitis / immunology*
-
Poliomyelitis / prevention & control
-
Poliovirus / drug effects
-
Poliovirus / immunology*
-
Poliovirus Vaccine, Inactivated / administration & dosage
-
Poliovirus Vaccine, Inactivated / immunology*
-
Vaccines, Inactivated / immunology
-
Vitamin D / analogs & derivatives*
-
Vitamin D / pharmacology
Substances
-
Poliovirus Vaccine, Inactivated
-
Vaccines, Inactivated
-
dihydroxy-vitamin D3
-
Vitamin D